NASDAQ:NYMX Nymox Pharmaceutical (NYMX) Stock Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free NYMX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.19▼$0.4752-Week Range N/AVolume932,700 shsAverage Volume94,622 shsMarket Capitalization$18.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Nymox Pharmaceutical alerts: Email Address Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) About Nymox Pharmaceutical Stock (NASDAQ:NYMX)Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.Read More Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. NYMX Stock News HeadlinesDecember 27, 2023 | markets.businessinsider.comNymox December 27 Message to ShareholdersDecember 27, 2023 | finanznachrichten.deNymox Pharmaceutical Corporation: Nymox December 27 Message to ShareholdersMarch 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.November 30, 2023 | finance.yahoo.comNymox Reports California Court Issues Preliminary Injunction Against Defendants Lanham, Riley, Cutler and OthersNovember 22, 2023 | finanznachrichten.deNymox Pharmaceutical Corporation: $250 Million Lawsuit Filed Against AscellaHealth by Nymox Accepted and Summons Issued in California CourtNovember 21, 2023 | markets.businessinsider.com$250 Million Lawsuit Filed Against AscellaHealth by Nymox Accepted and Summons Issued in California CourtNovember 9, 2023 | markets.businessinsider.comNymox Pharmaceutical Corporation Sues AscellaHealth For $250 MillionNovember 6, 2023 | finance.yahoo.comThe Committee to Restore Nymox Shareholder Value Provides Factual Update to Nymox Shareholders Regarding Special MeetingMarch 28, 2024 | Behind the Markets (Ad)Urgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.November 3, 2023 | financialpost.comNYMOX REPORTS NOTICE: California Court Issued A Temporary Restraining Order Enjoining Lanham, Riley, Cutler And Their Nevada Company After Court Hearing In Santa Ana, California, November 2, 2023October 27, 2023 | benzinga.comNotice: Nymox Informs Its Shareholders Not to Take Calls or Participate in An Unauthorized and Improper Shareholder MeetingOctober 26, 2023 | finanznachrichten.deNymox Pharmaceutical Corporation: Nymox Reports New NYMOZARFEX Marketing Application is Accepted For ReviewOctober 11, 2023 | finance.yahoo.comThe Committee to Restore Nymox Shareholder Value Issues Notice of Special Meeting of Nymox Pharmaceutical ShareholdersOctober 6, 2023 | businesswire.comBahamas Supreme Court Rules in Favor of Committee to Restore Nymox Shareholder Value: Orders Shareholder Meeting, Grants Injunction Freezing CEO SharesSeptember 26, 2023 | finance.yahoo.comNymox Pharmaceutical Corporation (NYMXF)September 25, 2023 | markets.businessinsider.comNymox Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPHAugust 29, 2023 | markets.businessinsider.comNymox Reports Completion of $2 Million Private PlacementJuly 18, 2023 | finanznachrichten.deNymox Pharmaceutical Corporation: Nymox Reports on U.S. Patent IssuancesJuly 18, 2023 | finance.yahoo.comNymox Reports on U.S. Patent IssuancesJuly 16, 2023 | venturebeat.comThe Committee to Restore Nymox Shareholder Value Soundly Rebuts Injurious Allegations Made by Nymox Pharmaceutical Corp Current ManagementJuly 12, 2023 | finance.yahoo.comNymox Announces Appointment Of Patrick Doody as Vice President and Member of the Board of Directors of NymoxJuly 9, 2023 | venturebeat.comRebuttal Letters Issued to Shareholders of NYMOX PHARMACEUTICAL CORP (“NYMX-Q”)July 8, 2023 | finanznachrichten.deNymox Pharmaceutical Corporation: NYMOX UpdateJuly 7, 2023 | financialpost.comNYMOX UpdateJuly 6, 2023 | investorplace.comWhy Is Nymox Pharmaceutical (NYMX) Stock Down 18% Today?July 6, 2023 | seekingalpha.comNymox Pharmaceutical receives potential delisting notice from NasdaqJuly 6, 2023 | msn.comNYMX Tanks after Receiving Delisting NoticeSee More Headlines Receive NYMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2014Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:NYMX CUSIPN/A CIK1018735 Webwww.nymox.com Phone(800) 936-9669Fax514-332-2227Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,589.50% Return on Assets-117.25% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / BookN/AMiscellaneous Outstanding Shares90,510,000Free Float41,637,000Market Cap$18.10 million OptionableOptionable Beta0.64 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Paul Averback DABP (Age 72)M.D., Founder, Chairman, CEO & Pres Comp: $660kMr. Randall J. Lanham Esq. (Age 59)J.D., Gen. Counsel, Sec., COO & Director Comp: $496.45kMs. Lin DoddQA and Compliance Mang.Mr. Christopher R. RileyChief Financial OfficerKey CompetitorsTrinity BiotechNASDAQ:TRIBBiomericaNASDAQ:BMRAARCA biopharmaNASDAQ:ABIOOncoCyteNASDAQ:OCXCardio DiagnosticsNASDAQ:CDIOView All Competitors NYMX Stock Analysis - Frequently Asked Questions How were Nymox Pharmaceutical's earnings last quarter? Nymox Pharmaceutical Co. (NASDAQ:NYMX) released its quarterly earnings data on Friday, November, 14th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The biopharmaceutical company had revenue of $0.08 million for the quarter. What other stocks do shareholders of Nymox Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Biocept (BIOC), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and CTI BioPharma (CTIC). This page (NASDAQ:NYMX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nymox Pharmaceutical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.